Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

Malaria, schistosomiasis and leishmaniases are among the most prevalent tropical parasitic diseases and each requires new innovative treatments. Targeting essential parasite pathways, such as those that regulate gene expression and cell cycle progression, is a key strategy for discovering new drug l...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Ming Jang, Arnold, Megan S.J., Xu, Weijun, Lancelot, Julien, Lamotte, Suzanne, Späth, Gerald F., Prina, Eric, Pierce, Raymond J., Fairlie, David P., Skinner-Adams, Tina S., Andrews, Katherine T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241585/
https://www.ncbi.nlm.nih.gov/pubmed/28107750
http://dx.doi.org/10.1016/j.ijpddr.2016.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241585/
https://www.ncbi.nlm.nih.gov/pubmed/28107750
http://dx.doi.org/10.1016/j.ijpddr.2016.12.005

Ejemplares similares